Video

Dr. Sabari on the Updated Results of the CHRYSALIS Study With Amivantamab in EGFR+ NSCLC

Joshua K. Sabari, MD, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab in patients with non–small cell lung cancer whose tumors harbored EGFR exon 19 deletion or L858R mutations.

Joshua K. Sabari, MD, an assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, discusses updated results from the phase 1 CHRYSALIS trial examining amivantamab (JNJ-61186372) in patients with non–small cell lung cancer (NSCLC) whose tumors harbored EGFR exon 19 deletion or L858R mutations.

Data from the trial were presented during the 2020 ESMO Virtual Congress and demonstrated promising results with this approach in a heavily pretreated patient population, according to Sabari. These patients had cMET- and C7S-mediated resistance and achieved a response rate of 43.5% with amivantamab in combination with lazertinib, says Sabari. Patients with treatment-naive disease who had exon 19 deletions and patients with exon 21 insertion mutations and were treated with the combination experienced a response rate of 100%, adds Sabari.

During the 2021 World Conference on Lung Cancer, the updated results from the cohort of patients with exon 20 insertion mutations were presented. In these patients, the an objective response rate of 40%, a clinical benefit rate of 74%, and a median duration of response of 11.1 months, says Sabari. Additionally, there was a median progression-free survival of 8.3 months. These updated results have the potential to be practice-changing and may be a valuable step forward for this patient

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity